[ad_1]
Cannabis consumers of metro Phoenix, get ready to roll. We’re on the cusp of 4/20, the biggest day of the year for stoners, potheads, casual users or anyone else with a love of the leafy green plant…
[ad_2]
Benjamin Leatherman
Source link

[ad_1]
Cannabis consumers of metro Phoenix, get ready to roll. We’re on the cusp of 4/20, the biggest day of the year for stoners, potheads, casual users or anyone else with a love of the leafy green plant…
[ad_2]
Benjamin Leatherman
Source link

[ad_1]
[
{
"name": "Air - MediumRectangle - Inline Content - Mobile Display Size",
"component": "18478561",
"insertPoint": "2",
"requiredCountToDisplay": "2"
},{
"name": "Editor Picks",
"component": "16759093",
"insertPoint": "4",
"requiredCountToDisplay": "1"
},{
"name": "Inline Links",
"component": "17980324",
"insertPoint": "8th",
"startingPoint": 8,
"requiredCountToDisplay": "7",
"maxInsertions": 25
},{
"name": "Air - MediumRectangle - Combo - Inline Content",
"component": "16759092",
"insertPoint": "8th",
"startingPoint": 8,
"requiredCountToDisplay": "7",
"maxInsertions": 25
},{
"name": "Inline Links",
"component": "17980324",
"insertPoint": "8th",
"startingPoint": 12,
"requiredCountToDisplay": "11",
"maxInsertions": 24
},{
"name": "Air - Leaderboard Tower - Combo - Inline Content",
"component": "16759094",
"insertPoint": "8th",
"startingPoint": 12,
"requiredCountToDisplay": "11",
"maxInsertions": 24
}
]
[ad_2]
David Abbott | Arizona Mirror
Source link

[ad_1]
Every Valley stoner’s favorite cannabis festival went up in a cloud of smoke on March 16 and 17. But in that very good weed sort of way…
[ad_2]
Kevin Hurley
Source link

[ad_1]
With the benefits of cannabis legalization still being debated throughout the country, one traveling magician is trying to destigmatize its use. Ben Zabin brought his “Smokus Pocus” show to Phoenix in early March as part of his nationwide tour…
[ad_2]
Donovan Growney | Cronkite News
Source link

[ad_1]
[
{
"name": "Editor Picks",
"component": "16759093",
"insertPoint": "4",
"requiredCountToDisplay": "1"
},{
"name": "Inline Links",
"component": "17980324",
"insertPoint": "8th",
"startingPoint": 8,
"requiredCountToDisplay": "7",
"maxInsertions": 25
},{
"name": "Air - MediumRectangle - Combo - Inline Content",
"component": "16759092",
"insertPoint": "8th",
"startingPoint": 8,
"requiredCountToDisplay": "7",
"maxInsertions": 25
},{
"name": "Inline Links",
"component": "17980324",
"insertPoint": "8th",
"startingPoint": 12,
"requiredCountToDisplay": "11",
"maxInsertions": 24
},{
"name": "Air - Leaderboard Tower - Combo - Inline Content",
"component": "16759094",
"insertPoint": "8th",
"startingPoint": 12,
"requiredCountToDisplay": "11",
"maxInsertions": 24
}
]
The company celebrated the expansion of its brand into Scottsdale for the first time by hosting a grand opening party on Feb. 23 with music, swag bags, nonmedicated tacos and ticket giveaways to “Bob Marley: One Love.” Because of course they did.
The Scottsdale dispensary is Mint’s sixth store in the Valley — the fifth one opened in the West Valley in February 2023. It also has six dispensaries in Michigan and one in Missouri. Located at 8729 E. Manzanita Drive, the Scottsdale dispensary is not far from Talking Stick Resort.
Cannabis fans know Mint for opening a first-of-its-kind cannabis kitchen in 2018, adding a drive-thru in 2020 and being the first to go 24 hours a day in 2022.
Mint also knows a thing or two about infused fundraisers and festivals.
Phoenix New Times joined the celebration in Scottsdale. Here are some of our favorite moments.
Employees at Mint cut the ribbon on the brand’s new dispensary in Scottsdale on Feb. 23.
Kevin Hurley
Customers pose with a glass pipe they won at the grand opening celebration of Mint’s Scottsdale location.
Kevin Hurley
An employee announces another giveaway at the grand opening celebration of Mint in Scottsdale.
Kevin Hurley
[ad_2]
Kevin Hurley
Source link

[ad_1]
Recreational sales in November 2023 weighed in at $83.5 million, while medical sales remained flat at about $25 million for the second month in a row, according to the latest report from the Arizona Department of Revenue.
The medical market dropped below $40 million in July 2022, trending downward to $30.4 million in May 2023. Since then, sales have not passed that mark and have hovered around $25 million.
Medical sales have declined consistently since a peak of $73.4 million in April 2021. Medical sales dropped to new lows seemingly every month.
Recreational sales, which began in late January 2021 after voters legalized sales in November 2020, have fluctuated between $80 million and $93.5 million since July 2022. Since then, they hit a high-water mark of $100 million in March 2023 and have since leveled out to the mid- to lower-$80 million range.
Through November 2023, medical cannabis sales for the year totaled more than $320.5 million and Arizonans purchased more than $978.1 million in recreational, for a total of nearly $1.3 billion.
Since January 2021, the cannabis industry has generated more than $4.2 billion in sales, with about $2.6 billion from recreational customers. Should the current trend continue, cannabis sales in 2023 should easily match the $1.4 billion total in 2022.
The state collects a 16% excise tax on recreational sales in addition to the standard sales tax; medical patients pay roughly 6% in state sales tax. Local jurisdictions charge an additional 2% or so for all marijuana sales.
In November 2023, the excise tax on adult-use marijuana sales yielded about $13.3 million, with medical bringing about $2 million into state coffers.
One-third of revenue raised by the recreational excise tax is dedicated to community college and provisional community college districts; 31% to public safety, including police, fire departments, fire districts and first responders; 25% to the Arizona Highway User Revenue Fund; and 10% to the justice reinvestment fund. That fund is dedicated to providing public health services, counseling, job training and other social services for communities that have been adversely affected and disproportionately impacted by marijuana arrests and criminalization.
The Arizona Department of Health Services has reported a steady decline in the medical cannabis program participation, as the number of qualifying patients continues to drop every month.
As of January, there were 113,694 qualifying patient cardholders, down from 115,914 in December 2023. At the height of the medical market, there were 299,054 qualifying patients prior to the advent of recreational sales.
In January, Arizona medical cannabis consumers purchased 4,100 pounds of marijuana in various forms, down from 4,636 reported in December 2023. Throughout 2023, Arizona medical marijuana patients purchased 65,596 pounds.
This story was first published by Arizona Mirror, which is part of States Newsroom, a network of news bureaus supported by grants and a coalition of donors as a 501c(3) public charity. Follow Arizona Mirror on Facebook and Twitter.
[ad_2]
David Abbott | Arizona Mirror
Source link

[ad_1]
EAST POINT, Ga. (Atlanta News First) – East Point has now joined a small but growing list of Georgia cities that have voted to decriminalize marijuana possession of an ounce or less.
Of the 535 cities in the state, East Point is just the 13th to make the move.
Now, people arrested for possession of one ounce or less of marijuana will be given a $75 fine or community service, but will not be punished with jail time.
The ordinance, unanimously approved by the East Point City Council on Dec. 19, almost identically mirrors a similar ordinance down the road in Atlanta.
East Point is the second city to decriminalize this year, following Camilla.
“Georgia is very, very behind the times when it comes to (decriminalization),” said Scotty Smart, a marijuana policy advocate with the group New Georgia Project.
Smart notes that Georgia has the fourth highest rate of simple marijuana possession in the entire country, and Black and brown residents are three to four times more likely to be arrested on that charge.
“Enactment of an ordinance concerning the offense of simple marijuana possession is further intended to prevent young people from entering the criminal justice system and avoiding the enduring stigma associated therewith,” reads part of the ordinance language.
The ordinance also states that decriminalization will also help open up police resources and eliminate costs “by reducing the amount of time police officers spend in connection with the arrest, processing and…
[ad_2]
MMP News Author
Source link

[ad_1]
POCOMOKE CITY, Md.-City leaders in Pocomoke City are implementing restrictions on marijuana business there. The mayor tells WBOC that the City Council passed a resolution Monday night establishing a six-month moratorium for marijuana businesses. This includes all aspects of marijuana business, such as growing, processing, and on-site consumption.
The City says the ordinance will be so leaders can establish proper zoning laws and figure out where marijuana establishments will fit best.
This moratorium on marijuana business goes into effect immediately in Pocomoke.
[ad_2]
MMP News Author
Source link

[ad_1]
The decline of Canada’s legal marijuana trade has led to two-thirds of marijuana dealers falling behind in their tax payments, according to a federal report.
“The total amount of unpaid cannabis excise duties has continuously been rising since legalization,” said a report by the Competition Bureau released May 26.
As of September 2022, 66 percent of licensees required to remit excise duties had an outstanding debt with the Canada Revenue Agency, and unpaid taxes last year totalled $52.4 million, according to “Planting the Seeds for Competition”, as first reported by Blacklock’s Reporter. The report said the total unpaid cannabis excise duties is projected to nearly double to $97.5 million this year.
The Competition Bureau wrote that following legalization in 2018, Parliament began taxing marijuana at $1 per gram plus GST, but with the average price per gram for dried cannabis falling since then, excise duties now take up a more significant portion of producers’ revenues, up to 30 percent or more.
The report stated that until recently, cannabis producers licensed under the excise duty regime were required to remit excise duties to the CRA on a monthly basis. However, many producers found this challenging since not all buyers pay for products on a monthly basis. The report noted that the Ontario Cannabis Store, for example, has 60 days to pay cannabis producers for their products.
The Department of Finance in Budget 2023 proposed to allow all cannabis…
[ad_2]
MMP News Author
Source link

[ad_1]
Marijuana legalization initiatives have appeared on ballots for decades as the legalization of cannabis at various levels has spread across the country.
Florida appears to be on track to have a question about legalizing recreational marijuana on the ballot in 2024, but the initiative is being challenged by state Attorney General Ashley Moody. Here is what to know about the proposed ballot initiative.
SCHUMER PROJECTS DEBT CEILING OPTIMISM AS PROGRESSIVES FRET ABOUT DEAL
The proposed 2024 ballot initiative
The initiative is spearheaded by the group Smart and Safe Florida, which is led by country music artists Howard and David Bellamy, and pushes for “a safe and legal cannabis industry in Florida.”
“About three-fourths of Florida voters support legalizing marijuana. It is clear that Floridians are more than ready to pass the laws necessary to establish a safe, legal cannabis industry for adults over 21 that establishes straightforward penalties for illegal sale or distribution, or violation of the regulations enacted,” Howard and David Bellamy said in a statement announcing the initiative in 2022.
The proposed amendment to the constitution would allow for the recreational use of marijuana by adults 21 and older in the Sunshine State, which would put it in line with alcohol and tobacco laws in Florida.
Requirements to pass the initiative
To get…
[ad_2]
MMP News Author
Source link

[ad_1]
Kentucky’s new medical marijuana law becomes effective by January 1, 2024, after implementing rules … [+]
Kentucky has become the 38th state in the U.S. to legalize cannabis for medical use. While the new law legitimizes the use of marijuana for medical purposes, it fails to afford lawful users employment protections, permitting employers to enforce “zero-tolerance” workplace policies. Further, it places specific obligations on workers who use medical cannabis to prove their innocence regarding impairment.
The law comes after an executive order issued by Kentucky Governor Andy Beshear in 2022 that allowed Kentucky residents with qualifying medical conditions to possess and use small amounts of legally purchased medical marijuana. Legalization has been an important issue for Beshear, a Democrat, who governs a state with a Republican legislature.
Under the new law, individuals eligible for treatment of “qualifying medical conditions” may possess a 30-day supply of cannabis at their residence and a 10-day supply on their person. While individuals may not smoke marijuana, vaping is permitted. Qualifying medical conditions include cancer, chronic, severe, intractable, or debilitating pain, epilepsy or other seizure disorders, multiple sclerosis, muscle spasms or spasticity, chronic nausea, post-traumatic stress disorder, or any other condition identified by the state’s regulator. Individuals under the age of 18 are eligible for treatment…
[ad_2]
MMP News Author
Source link

[ad_1]
602724327
Mozilla/5.0 (Windows NT 6.3; WOW64; rv:33.0) Gecko/20100101 Firefox/33.0
e06b67b60930ed64d56ee1e3454696660b4a3640
1
[ad_2]
MMP News Author
Source link

[ad_1]
David Abbott
(Arizona Mirror) Total Arizona marijuana sales in 2022 mirrored the total from 2021, the first year of the legal adult use market, but the paths that each year reached $1.4 billion in sales were strikingly different.
In 2021, medical marijuana sales were the driving factor, accounting for nearly 55% — about $760 million — of the total. In 2022, the recreational cannabis market soared to nearly 70% of sales, or more than $950 million, as the medical market crashed to slightly more than $500 million.
The recreational market closed out 2022 with its best monthly total in December, clocking in at about $86.6 million, a slight increase from the $85.8 in November sales. Medical marijuana sales were stagnant, with a slight drop from November to December 2022 from $31.9 to $31.1 month-to-month.
The overall total cannabis sales for both markets since the advent of legal adult-use in January 2021 is $2.9 billion.
Medical sales have declined nearly every month since April 2021, with few exceptions. Sales that month reached $73.2 million, but with the exception of July 2021 when sales hit $71.6 million after a $5 million drop in June that year, medical sales have never come close to that total again. The last time medical users spent more than $50 million in a month was April 2022.
Recreational sales have remained robust as patients flock to the recreational market and manufacturers of higher-potency medical marijuana products — edibles and other ingestables — have…
[ad_2]
MMP News Author
Source link

[ad_1]
Jan. 5, 2022 – Nearly 1 in 5 people in the U.S. age 12 or older said they used marijuana in 2021, according to new federal survey results.
Among the 52 million people who said they used marijuana in the past year, young adults ages 18 to 25 were the most likely to report doing so, at 35%. That age group was also the most likely to report having a mental illness in the past year, at 34%.
The findings were part of the annual National Survey on Drug Use and Health released Wednesday by the Substance Abuse and Mental Health Services Administration.
“As the findings make clear, millions of Americans young and old faced mental health and substance use challenges – sometimes both at once – during the second year of the pandemic,” U.S. Department of Health and Human Services Secretary Xavier Becerra said in a statement.
The survey took place both in person and online, and due to changes in how it was done, officials said the data cannot be accurately compared to the results of previous years. But there were many signs that drug use and mental illness increased with the start of the COVID-19 pandemic.
Overall, the 2021 survey results showed that 57.8% of people age 12 or older currently use tobacco, alcohol, or an illicit drug, including 47.5% who said they drink alcohol, 19.5% who said they use tobacco products, and 14.3% who said they use illicit drugs. Current use was defined as using a substance within the month before taking the survey.
In addition to being the most prevalent age group among marijuana users and those with mental illness, 18- to 25-year-olds were the most likely to have a substance use disorder in the past year. The survey showed that 94% of people with a substance use disorder did not get treatment, and researchers wrote that “nearly all people with a substance use disorder who did not get treatment at a specialty facility did not think they needed treatment.”
[ad_2]

[ad_1]
Nov. 10, 2022 – I was in the exam room, saving my big question for last, as one does.
It was my first meeting with my new primary care doctor in Colorado, and I was impressed with his fluid citations and advice from recent studies on heart disease, exercise injuries, and musculoskeletal pain – three of my major sore points.
So far, so good.
Then I ventured my last question. “I’ve been having sleep difficulties ever since my older son was born.” (Note: That was during the first Bush administration.) “But now that I’m in Colorado, I wonder if cannabis might help me through the night? I hear it’s good for that.”
Suddenly, my doctor clammed up.
“I’ve heard some things, too,” he told me. “But I can’t advise you on that, because I could lose my license.”
He could no more recommend cannabis than he could heroin or ecstasy — because all are designated Schedule 1 drugs on the federal level. (Though that could change, given President Joe Biden’s recent moves toward marijuana reform.)
So now I had a choice: I could “just say no to drugs,” as Nancy Reagan encouraged me to do. Or I could begin experimenting. As a health journalist for two decades, I know anecdotal evidence is often no more than wishful thinking. And yet, my standards slip when I stare at the ceiling at 3 a.m., and dawn is a long way off.
In an age of red-versus-blue discord, cannabis is one of the few arguably purple issues. Thirty-seven states, D.C., and three territories have passed comprehensive medical marijuana laws, permitting treatment for 42 conditions. Twenty-one states, DC, and two territories allow adults to use it for whatever reason, from pain relief to partying. Which leaves only Kansas, Nebraska, and Idaho standing with federal lawmakers from 1970, in agreeing that cannabis is just as addictive and dangerous as heroin, cocaine, LSD, and ecstasy.
“Most [doctors] are not trained in cannabinoid medicine,” says Erik Smith, MD, a Philadelphia doctor and physician partner with Veriheal, a healthcare technology company that provides personalized cannabis education to patients. “And they’re under a lot of pressure from the healthcare system, because cannabis is a Schedule I drug. So, patients have to go by word of mouth, outside the realm of medicine.”
When I was an editor at a health magazine, the surest way to kill any story idea was to dismiss it as being based on mere “anecdotal evidence,” which we regarded as a synonym for “fairy dust” or “snake oil.”
No double-blind study, no deal.
Smith didn’t have that luxury. He took his training in obstetrics and gynecology. And when his pregnant patients came to him with refractory nausea and vomiting, he went off the books, and told them, “I know somebody who can help you.”
Right: a cannabis dealer.
And while you register shock that an MD would recommend an extra-pharmaceutical treatment, consider this: Opioids are an approved drug, and they killed 68,630 people via overdoses in 2020 alone, according to the CDC. Deaths by cannabis overdose are either nonexistent or exceedingly rare.
That was part of Smith’s calculation, when he took over a roster of patients who were (a) pregnant, and (b) self-medicating with opioids and other drugs, to the point of addiction.
“Nobody wanted to touch these patients,” he says. “We started with addiction specialists and began working with the synergistic effects of cannabis to help our patients go off opioids. There were better outcomes, and they were able to deliver their babies.”
The Politics of Pot
Smith wasn’t the only one listening to patients’ experiences with cannabis. After California approved medical marijuana in 1996, momentum began to build. The movement went national in 2013, when Sanjay Gupta, MD, on CNN, told the story of Charlotte Figi, a five-year old Colorado girl with Dravet Syndrome, a form of epilepsy. She was suffering 300 grand mal seizures a week, until her staunchly anti-drug parents heard about a California boy whose seizures were stopped by a cannabis strain high in cannabidiol, or CBD. In desperation, they worked with a cannabis producer in Colorado Springs to grow a high-CBD strain that would be called Charlotte’s Web. Her seizures stopped, and a DIY movement was born, often among people who, like the Figi family, , were surprised to turn to a notorious drug for help and healing. (Sadly, Charlotte died in 2020, likely due to COVID.)
G. Malik Burnett, MD, is an addiction medicine specialist in Baltimore, and co-author of a study called “Policy Ahead of the Science: Medical Cannabis Laws Versus Scientific Evidence.” That sums up the problem with cannabis therapies today: The treatment cat is out of the medical-research bag, and running all over the 42-odd conditions that justify a medical marijuana card — and a hundred others that do not.
As Burnett’s study says: “U.S. medical cannabis laws are in conflict with federal law and often with science as well.”
And yet, Burnett is far from a cannabis naysayer. In his study, he notes that the most commonly included conditions on state lists — cachexia/weight loss, muscle spasticity associated with multiple sclerosis, nausea and vomiting, chronic pain, and seizures — are also the ones with the most evidence that cannabis therapy works. But the lists also stray into areas where there is no evidence (ALS, arthritis, cancer), limited evidence (autism, HIV/AIDS, opioid-use disorder), or even evidence of potential harm (glaucoma, depression, PTSD).
Burnett recently testified before Congress in support of decriminalizing cannabis at the national level. His reasoning: to address the prejudicial way drug laws have been applied against people of color, and to help clear the 100-year logjam against medical studies of marijuana. Only then will the evidence sort itself out into what works and what doesn’t.
Cannabis was common in patent medicines in the early 1900s, but as the plant began to travel north with immigrant workers from Mexico, U.S. officials woke up to the “threat.” With mounting hysteria, they passed increasingly draconian laws to prohibit cannabis use for anything at all, including better health. The Marihuana Tax Act of 1937, passed over the protests of the American Medical Association, began the demonization process. (Regulators insisted on calling it “marihuana,” in fact, to emphasize that foreign people were using it, and that it was suspect for that reason.)
Charlotte’s dramatic tale led to lots of personal testimony before state legislatures, by people whose stories were hard to ignore: veterans suffering from post-traumatic stress disorder, parents of kids with epilepsy, people with AIDS, people with chronic pain , and those recovering from drug addiction. All of these, and more, were flouting federal law by using cannabis to treat their afflictions. Clinical trials were unavailable because cannabis research was illegal, too. But word of mouth proved powerful, and legalization took off at the state level.
The Healing History of Cannabis
For all the federal chest-pounding against cannabis, there’s a certain irony there, too. The first U.S. patent for cannabis-as-medicine is held by none other than the Department of Health and Human Services. They applied for the patent in 1999 for cannabinoids to be used as anti-inflammatories and neuroprotectants. Something was in the air, and not just at Grateful Dead revivals.
The high-producing ingredient in cannabis – delta-9-tetrahydrocannabinol, or THC — was first isolated in 1964, by Israeli researcher Raphael Mechoulam and his team at the Hebrew University of Jerusalem, who were free to chase their research wherever it might lead. (Israel remains the world leader in cannabis research, says Smith.) Twenty years later, they discovered that the human body has a multitude of cannabinoid receptors in the brain, gut, skin, immune system, organs, and reproductive system. A study in Cerebrum called it “literally a bridge between body and mind.” These receptors are activated by endogenous cannabinoids. That is: cannabinoids produced by the body’s own internal dispensary. Soon the endocannabinoid system, or ECS, took its place alongside the circulatory system, nervous system, immune system, and endocrine system, as a primary body regulator.
“It led researchers to look at the endocannabinoid system for lots of additional therapeutic possibilities,” says Burnett.
And suddenly exogenous cannabinoids—from the cannabis sativa plant—were gaining credibility as healing agents as well, first from the self-medicating public, but also from scientists. The latter were very late to the game: Cannabis had been cultivated for health reasons for 11,000 years, according to archaeological discoveries in China and elsewhere. Even Queen Victoria signed on; her personal doctor prescribed cannabis tinctures to help soothe her painful menstrual cycles.
Burnett wasn’t willing to take her word for it, of course. In “Policy Ahead of the Science,” he and two collaborators gathered the evidence — still less than definitive but growing — of cannabis’s effectiveness for all 42 conditions. Among them: multiple sclerosis, cancer, ALS, HIV/AIDS, Crohn’s disease, and epilepsy.
If those maladies seem all over the place, it’s because the ECS is all over the body, as well.
Users Ahead of the Research
Lev Spivak-Spindorf, 40, didn’t need to be told that cannabis is effective in treating Crohn’s. He discovered it all by himself. Growing up in Michigan, he began experiencing cramping, abdominal distress, and appetite challenges when he was 15.
“I was diagnosed with Crohn’s, and they prescribed prednisone as an anti-inflammatory,” he says. “Any improvement felt amazing.”
But he was also experimenting with cannabis at this time, as teens will do. (Note: There is some evidence that cannabis may harm developing brains.) Spivak-Spindorf noticed a correlation between his cannabis use and a lessening of his symptoms. Now he treats his condition with indica strains (said to be sedating, compared with sativa strains, which are thought to be more invigorating), taking prophylactic doses, say, before a Thanksgiving meal that might rile his digestive tract.
“I’m not a medical doctor. I can’t say that cannabis has cured me,” he says. “But I will say that, after my last couple of colonoscopies, my doctors have told me that I really don’t have Crohn’s anymore.”
Based on this experience, and his education as a geologist, Spivak-Spindorf eventually gravitated to the cannabis industry, as chief science officer for PSI Labs, a cannabis testing facility in Michigan.
“The fun part of being in this industry is watching products evolve and making them safer,” he says.
Adam Young knows something about devoting a career to cannabis. He works at Realm of Caring, a Colorado-based nonprofit that was launched by Charlotte Figi’s mom, Paige. Their volunteers have counseled 75,000 people worldwide on how to implement cannabinoid healing protocols, basing their advice on the experiences of other users, 800 peer-reviewed articles, and training in regulations and medical-cannabis history. Young and his associates have also created a giant database of patient reactions to various cannabis regimens, which is “anecdotal evidence” writ large. They also publish scientific studies based on that data.
Young gained valuable experience with cannabis protocols in 2012, when his mother had multiple myeloma cancer.
“She was down to 65 pounds” from her radiation and chemotherapy treatments, says Young, “so I packed up all my stuff and moved to be with her.”
His mother was expected to live for just 5 more months, and the treatments were debilitating. So Young and his mother decided to “try something new.” Young researched protocols for people with wasting syndrome, which impacted many AIDS patients during that pandemic. Through his connections in the cannabis community, where he counseled non-violent drug offenders, he found a concentrated form of cannabis oil that might help his mom. Her doctors backed off from the unfamiliar therapy, telling them: “We can’t work with you.”
But they persevered. “In only 2 months, there was a reversal of what I had seen. She was back up to 95 pounds,” Young says. “I had my mom back.”
Experimenting with Cannabis: Finding the Right Plan for You
So what about me and my health issues? I really did want to talk to a doctor, so I turned to Veriheal (the cannabis-education company Smith consults for).
For $110, Veriheal will arrange a telehealth consultation with a medical professional. In my case, it was Carlie Bell, ND. She’s a naturopathic physician in Houston, having completed undergraduate studies in pre-med, plus a four-year graduate program in therapies that help the body heal itself. Bell is also a cannabis educator at Saint Louis University, working with practitioners who want to give better answers than my doctor did.
She crackled to life on my computer via a telehealth app, and soon we were deep in the weeds of my sleep issues. Bell listened to my sleeplessness woes, cited research on the ECS, and recommended that I commence a protocol using full-spectrum CBD (meaning it’s derived from whole-flower cannabis). She proposed that I take it in tincture form, 2 hours before bedtime, and hold it under my tongue for 45 seconds to a minute. The benefits: The CBD would be absorbed through mucous membranes in my mouth, for an immediate calming effect, but the amount that I swallowed would work its way through my digestive tract, for a longer-lasting soporific effect.
I experimented based on the advice and found a plan that worked for me: I start the night with a prescription to help with my restless legs syndrome, then use a sublingual cannabis if I am wakeful in the middle of the night. It hasn’t cured my insomnia, but it has given me treatment options I didn’t have before. I awake refreshed, with no grogginess — a common problem I had when I was taking prescription sleeping pills.
Bell reiterated cautions I was to hear half a dozen times, as I completed research for this story:
[ad_2]